| 621 |
A Quality Care Dosing Guidelines |
| 089 |
Adoptive Cell Therapies for Melanoma |
| 246 |
Ampyra dalfampridine |
| 021 |
Anti-Migraine Policy |
| 054 |
Anti-Parkinsonism Drugs |
| 013 |
Antihyperlipidemics |
| 027 |
Antisense Oligonucleotide Medications |
| 011 |
Asthma and Chronic Obstructive Pulmonary Disease Medication Management |
| 621 |
B Quality Care Dosing Guidelines Drug List |
| 006 |
Botulinum Toxin Injections |
| 099 |
Carelon Oncology Medication Management Program |
| 019 |
CNS Stimulants and Psychotherapeutic Agents |
| 705 |
Compound Medications Exclusion Drug List |
| 704 |
Compound Medications Inclusion Drug List |
| 579 |
Compounded Medications |
| 002 |
Cox II Inhibitor Drugs |
| 041 |
Diabetes Step Therapy |
| 049 |
Drug Management & Retail Pharmacy Prior Authorization Policy |
| 251 |
Drug Management and Prior Authorization |
| 408 |
Drugs for Cystic Fibrosis |
| 092 |
Drugs for Macular Degeneration and Diabetic Eye Disease |
| 572 |
Drugs for Weight Loss |
| 023 |
E Form medication prior auth instruction |
| 009 |
Elzonris (tagraxofusp-erzs) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm |
| 162 |
Entyvio ( Vedolizumab ) Policy |
| 262 |
Erythropoietin, Recombinant Human and Hypoxia-Inducible Factor Inhibitors |
| 087 |
Esketamine Nasal Spray (SpravatoTM) and Intravenous Ketamine for Mental Health Conditions |
| 113 |
Fentanyl, oral-transmucosal |
| 022 |
Gene Therapies for Duchenne Muscular Dystrophy |
| 168 |
Gene Therapies for Hemophilia A or B |
| 106 |
Gene Therapies for Metaloleukodystrophy |
| 241 |
Gene Therapy for Cerebral Adrenoleukodystrophy SKYSONA |
| 056 |
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Related Drugs for the Treatment of Type 2 Diabetes |
| 257 |
Growth Hormone and Insulin-like Growth Factor |
| 063 |
Heart Failure and Hypertrophic Cardiomyopathy (HCM) Policy |
| 697 |
HETLIOZ tasimelteon |
| 430 |
Home Infusion Therapy Prior Authorization Form |
| 296 |
Home Total Parenteral Nutrition TPN |
| 360 |
Human Anti hemophilic Factor |
| 131 |
Hypoactive Sexual Desire Disorder (HSDD) Policy |
| 004 |
Immune Modulating Drugs |
| 310 |
Immunoglobulins Policy |
| 010 |
Immunomodulators for Skin Conditions |
| 440 |
Influenza Drugs Tamiflu and Relenza |
| 017 |
Injectable Asthma Medications |
| 071 |
Injectable Specialty Medication Coverage |
| 427 |
Injections for Osteoarthritis |
| 052 |
Interferons Alpha and Gamma |
| 434 |
Massachusetts Standard Form for Medication Prior Authorization Requests |
| 034 |
Medical Benefit Prior Authorization Medication List |
| 083 |
Medications for Sickle Cell and Beta Thalassemia |
| 840 |
Methotrexate Step Therapy |
| 946 |
Monoclonal Antibodies for Treatment of Alzheimer's Disease |
| 839 |
Multiple Sclerosis Prior Auth Policy |
| 062 |
Mupirocin Step Policy |
| 005 |
New Drug Approval Program |
| 433 |
Noncovered Drug List |
| 123 |
Nononcologic Uses of Rituximab |
| 409 |
Oncology Drugs |
| 346 |
Ophthalmic Prostaglandins |
| 102 |
Opioid Medication Management |
| 170 |
Overactive Bladder Medications |
| 344 |
Pharmacy Hepatitis C Medication Management |
| 051 |
Pharmacy Specialty List |
| 033 |
Pharmacy-MED_UM_Policy_SP |
| 057 |
Pregabalin (Lyrica and Lyrica CR) |
| 030 |
Proton Pump Inhibitors |
| 422 |
RSV Immunoprophylaxis |
| 093 |
Soliris, Ultomiris, Complement 3 Glomerulopathy (C3G), Myasthenia Gravis, Paroxysmal nocturnal hemoglobinuria (PNH), and Neuromyelitis Optica Policy |
| 093 |
Soliris, Ultomiris, Complement 3 Glomerulopathy (C3G), Myasthenia Gravis, Paroxysmal nocturnal hemoglobinuria (PNH), and Neuromyelitis Optica Policy |
| 304 |
Special Foods |
| 044 |
Spinal Muscular Atrophy (SMA) Medications |
| 681 |
Sublingual Immunotherapy with Allergen-specific Extracts - SLIT |
| 105 |
Supportive Care Treatments for Patients with Cancer |
| 426 |
Topical Ocular Hydrating Agents |
| 345 |
Topical Testosterone |
| 014 |
Veozah Step Policy |
| 008 |
Zolgensma (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy |